Compare KNF & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KNF | PTCT |
|---|---|---|
| Founded | 1917 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.0B | 5.5B |
| IPO Year | 2023 | 2006 |
| Metric | KNF | PTCT |
|---|---|---|
| Price | $87.77 | $64.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 17 |
| Target Price | ★ $96.50 | $79.41 |
| AVG Volume (30 Days) | 577.6K | ★ 1.0M |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 264.48 |
| EPS | 2.76 | ★ 7.78 |
| Revenue | ★ $3,146,012,000.00 | $264,734,000.00 |
| Revenue This Year | $6.17 | N/A |
| Revenue Next Year | $4.37 | $22.81 |
| P/E Ratio | $32.07 | ★ $8.58 |
| Revenue Growth | 8.52 | ★ 36.19 |
| 52 Week Low | $58.72 | $35.95 |
| 52 Week High | $101.02 | $87.50 |
| Indicator | KNF | PTCT |
|---|---|---|
| Relative Strength Index (RSI) | 60.15 | 25.11 |
| Support Level | $76.66 | $57.74 |
| Resistance Level | $94.23 | $68.44 |
| Average True Range (ATR) | 3.57 | 2.85 |
| MACD | 0.10 | -0.42 |
| Stochastic Oscillator | 58.57 | 10.94 |
Knife River Holding Co is an aggregates-led construction materials and contracting services provider. The segments of the company include West, Mountain, Central, and Energy Services. Each geographic segment offers a vertically integrated suite of products and services, including aggregates, ready-mix concrete, asphalt, and contracting services, while the Energy Services segment, which has locations throughout the company's geographic footprint, produces and supplies liquid asphalt and related services, for use in asphalt road construction, and is a supplier to some of the other segments.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.